Following ten years studying the intestinal microbiota and recognizing its integral place in human health, Tomas’ vision is to deliver the benefits of the microbiome to medical applications. An engineer with a PhD in biology, Tomas’ prominent expertise on the microbiome resulted in the founding of PharmaBiome where he established the first platform technology for product development in the microbiome field. Tomas is convinced that microbiome-based therapies will revolutionize medicine, and is excited to actively contribute towards this great innovation in healthcare.
Trained as a biochemist, Florian co-founded his first company after completing his PhD in protein characterization at the University of Zurich. In 2016, he joined PharmaBiome as director of operations, to drive the development and implementation of analytic technologies. With his startup experience and flair for innovative technical solutions, Florian thrives in the fast pace of PharmaBiome’s evolution from the lab to the human gut.
After graduating in microbiology from the ETH Zurich, Manuel spent more than 10 years in private banking and consulting, gaining a deep knowledge of the aspects essential to business success. In 2012, Manuel founded his first company, followed by key roles in the management of other fast-growing start-ups. Manuel brought these strong entrepreneurial skills to PharmaBiome in 2016. In addition to his profound knowledge in corporate and financial business, Manuel has a unique flair for corporate governance and business development.
During her master in food science and technology at ETH Zurich, Fabienne discovered the potential of the microbiome, with a thesis directed towards the mechanistic understanding and modeling of the human gut microbiota interactions. She earned the ETH medal for outstanding work, setting the stage for her research at PharmaBiome where she continues to develop and integrate formulation, optimization and production technologies.
During her master in microbiology at ETH Zurich, Laura’s thesis focused the modulation of the intestinal microbiota through dietary fiber. Her experience with anaerobic microbes equipped her to join the PharmaBiome team, where she co-developed the anaerobic culture and isolation platforms used in product development. She currently directs research on the microbial metabolism and interactions.
During his master in bioinformatics at ETH Philipp developed tools to analyze mixed microbial products and their behaviour in organisms. Philipp is part of the bioinformatics group at Pharmabiome where he implements new technologies to further advance the analysis and development of novel bacterial consortia.
After his training as bio-technician in different laboratories at ETH Zurich, an internship at the University of Lincoln, New Zealand, served to deepen his knowledge and enlarge his skillset. Upon his return to Switzerland in 2016 Markus joined PharmaBiome. Within his position as lab manager, he supports the fundamental task of the PharmaBiome team, bringing valuable technical, quality control and management skills to the lab.
Carmen received her master in microbiology from University of Lausanne and gained extensive experience in the microbiology of pathogenic bacteria as research assistant and laboratory technician in different labs. With a broad methodological portfolio, Carmen acts as lab manager, runs the analytical methods and supports research and development of our next generation therapeutics.
With a broad background spanning geology, molecular biology and ecology, Marco completed a PhD in environmental microbiology at ETH Zurich where he developed his passion for microbial ecology and computational biology. He joined the PharmaBiome team in 2016, taking the lead for bioinformatics, where he assures establishment and implementation of cutting-edge approaches to microbial ecology and phylogeny.
Head of the Clinic of Gastroenterology at University Hospital Zurich with over 25 years of clinical experience, Gerhard Rogler is a world renowned expert in his field. Gerhard heads the Swiss Inflammatory Bowel Disease (IBD) cohort, is a member of the International Organization of IBD Research (IOIBD) and sits on the Governing Board of the European Crohn’s and Colitis Organization (ECCO). He has published over 450 scientific articles and actively performs Fecal Microbiota Transplantation (FMT) as a therapy for recurrent Clostridium difficile Infection (rCDI). Gerhard is an experienced medical advisor to pharmaceutical companies with a clear understanding of market needs. As a member of the board, he supports a fast and patient-oriented implementation of PharmaBiome’s developments.
Christophe Lacroix is professor of Food Biotechnology at ETH Zurich and a world-leading expert in food biotechnology and the production of beneficial microbes. With over 18 years of experience in the field of intestinal fermentation modeling and technology of strict anaerobic gut microbes, he supports PharmaBiome’s platform development. Before establishing the professorship for Food Biotechnology at ETH Zurich in 2002, Christophe was professor of Dairy Biotechnology at the Université Laval, Québec, Canada, from 1985 to 2002. He has published over 280 scientific articles in peer-reviewed journals and has a long record of accomplishment of translational research in academia and in collaboration with food and biotech industries.
Alexey has an engineering background that he completed with a finance education. With over 15 years of experience and senior management positions in banking and corporate finance, he contributes deep understanding of finance and the financial markets to the board of directors. Alexey joined the Board of PharmaBiome in 2018 and supports the management team with his competencies in finance.
Serial entrepreneur in the life science and healthcare fields. Nuno’s experience includes company building, deal closure, fundraising, investment, and M&A. Nuno is also a Professor, until recently at the MIT Portugal program and now at NOVA University’s School of Business and Economics. He is Chairman of the Investment Committee of the 200M Fund, and a shareholder, advisor or board member of various companies and academic organizations.”
Entrepreneur and general manager of digital and communications businesses. Executive leader in healthcare in strategic and operational roles. Deep and broad expertise in hospital, specialty care and rare diseases (Roche, Genentech, Shire). Built therapy areas and franchises. Strategic and operational business leadership. Business development, market development, market expansion and competitive market share gain. Hands-on expertise in Europe, US and Asia.
Digital healthcare pioneer and entrepreneur with over 15 years of experience and a proven international track record of creating and building leading innovations, selling brands, as well as delivering fully integrated solutions that generate outstanding results. Chris is a dedicated and inspirational leader that builds and coaches multifunctional high performing teams.